Clinical Trial Detail

NCT ID NCT02583893
Title Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Sidney Kimmel Cancer Center at Thomas Jefferson University
Indications

acute myeloid leukemia

Therapies

Cytarabine + Etoposide + Mitoxantrone + Sirolimus

Age Groups: adult senior

Additional content available in CKB BOOST